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Abstract
Background/Aims: MicroRNAs (miRNAs) are short non-coding regulatory RNAs that control gene expression and play an
important role in cancer development and progression. However, little is known about the role of miRNAs in chronic
myeloid leukemia (CML). Our objective is to decipher a miRNA expression signature associated with CML and to determine
potential target genes and signaling pathways affected by these signature miRNAs.
Results: Using miRNA microarrays and miRNA real-time PCR we characterized the miRNAs expression profile of CML cell
lines and patients in reference to non-CML cell lines and healthy blood. Of all miRNAs tested, miR-31, miR-155, and miR-564
were down-regulated in CML cells. Down-regulation of these miRNAs was dependent on BCR-ABL activity. We next analyzed
predicted targets and affected pathways of the deregulated miRNAs. As expected, in K562 cells, the expression of several of
these targets was inverted to that of the miRNA putatively regulating them. Reassuringly, the analysis identified CML as the
main disease associated with these miRNAs. MAPK, ErbB, mammalian target of rapamycin (mTOR) and vascular endothelial
growth factor (VEGF) were the main molecular pathways related with these expression patterns. Utilizing Venn diagrams we
found appreciable overlap between the CML-related miRNAs and the signaling pathways-related miRNAs.
Conclusions: The miRNAs identified in this study might offer a pivotal role in CML. Nevertheless, while these data point to a
central disease, the precise molecular pathway/s targeted by these miRNAs is variable implying a high level of complexity of
miRNA target selection and regulation. These deregulated miRNAs highlight new candidate gene targets allowing for a
better understanding of the molecular mechanism underlying the development of CML, and propose possible new avenues
for therapeutic treatment.
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Introduction
Chronic myeloid leukemia (CML) is one of the most extensively
studied and, probably, best understood neoplasms. The cytoge-
netic hallmark of CML is the Philadelphia chromosome (Ph),
created by a reciprocal translocation between chromosomes 9 and
22 (t[9;22] [q34;q11]). This translocation results in the formation
of a hybrid bcr-abl oncogene on chromosome 22, which codes for
a deregulated tyrosine kinase. BCR-ABL activates multiple signal
transduction pathways, including mitogen-activated protein kinase
(MAPK), phosphatidylinositol 3 kinase, STAT5/Janus kinase, and
Myc. BCR-ABL activity leads to uncontrolled cell proliferation
and reduced apoptosis, resulting in the malignant expansion of
pluripotent stem cells in bone marrow [1]. Since CML is caused
by this distinct genetic lesion it was possible to design an effec-
tive targeted molecular therapy which selectively inhibits the
aberrant BCR-ABL tyrosine kinase. Imatinib mesylate (STI-571
or Gleevec), is the first BCR-ABL tyrosine kinase inhibitor (TKI)
to be used for the treatment of CML [2]. Imatinib is a small-
molecule drug that competitively binds the ATP-binding site of
BCR-ABL thus preventing a conformational switch to the active
form of the oncoprotein. This inhibits BCR-ABL autophospho-
rylation, interferes with its activation and blocks its downstream
signal transduction.
MicroRNAs (miRNAs) are a family of 19–24 nucleotide non-
coding RNAs, which affect the regulation of gene expression in
eukaryotic cells by binding to a 39-untranslated region (39 UTR)
within target messenger RNAs (mRNAs). MiRNAs are transcribed
by RNA polymerase II as long primary transcripts (pri-miRNAs)
and undergo sequential processing to produce mature miRNAs
[3,4]. MiRNAs play important roles in many cellular processes
such as development [5], stem cell division [6,7], apoptosis [8,9]
and cancer [10,11]. MiRNAs regulate gene expression by either
inhibiting translation or promoting degradation of specific mRNA
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yet these miRNAs may regulate around 30% of the protein-coding
genes [12]. This suggests not only their importance in various
regulatory pathways, but also their potential for manipulation.
MiRNAs themselves have been shown to act both as tumor
suppressors and as oncogenes, which can promote tumor growth.
In addition, aberrant miRNA levels, specifically an overall
downregulation, is observed in many cancers, as compared to
their normal tissue counterparts [13,14]. Recently, a growing body
of evidence has implicated specific miRNAs in the pathogenesis of
a variety of solid tumors (ovarian, breast and colorectal cancers
among others) and hematological malignancies (chronic lympho-
cytic leukemia (CLL), B-cell lymphomas, acute promyelocytic
leukemias, acute lymphocytic leukemia (ALL) and CML) [15,16].
Most publications on miRNA expression in CML explore the
expression of specific miRNAs [17,18,19,20,21]. Agirre et al [17]
revealed decreased expression of miR-10a in CML-derived
CD34
+ bone marrow cells compared with healthy controls.
Venturini et al [18] found increased expression of miR-17-5p in
CML-derived CD34
+ peripheral blood cells though this was
disputed by Hussein et al [21] who found no significant difference
in the expression of this miRNA in CML-derived bone marrow
cells compared to healthy controls. In this same paper, CML-
derived cells had a tendency for higher expression levels of miR-
155 and miR-223 in a subfraction of cases which was, however,
not significant. Overall, the data regarding CML specific miRNA
expression is inadequate and sometimes inconclusive and the role
of miRNAs in CML is still poorly understood. To better elucidate
the significance of differential miRNA expression in CML, it is
crucial to examine miRNAs expression profiles through micro-
array analysis in normal and CML tissues or cell lines.
Here, we profiled miRNAs expressed in the CML cell line
K562, as compared to its healthy counterpart, normal blood. With
the aid of unsupervised hierarchical clustering we found that
healthy blood samples were clustered separately from K562 cells.
Following miRNA real-time PCR validation, we have determined
that miR-31, miR-155, and miR-564 are downregulated in CML
cell lines and patients in comparison to non-CML cell lines and
healthy blood. Downregulation of these miRNAs is presumably
mediated by BCR-ABL tyrosine kinase activity. Bioinformatics
analysis revealed predicted targets and affected pathways of the
deregulated miRNAs. As expected, in K562 cells, the expression of
several of these targets was inverted to that of the miRNA
putatively regulating them. Reassuringly, the analysis identified
CML as possibly associated with major deregulation of these
miRNAs and MAPK, ErbB, mammalian target of rapamycin
(mTOR) and and vascular endothelial growth factor (VEGF) as
the main molecular signaling pathways regulated by these
miRNAs. Overall, our data indicate that these deregulated
miRNAs and their putative targets may play a pivotal role in
the biology of CML. Consequently, these miRNAs may serve as
potential diagnostic and prognostic biomarkers and with further
investigation may be used as possible therapeutics for patients
suffering from CML.
Material and Methods
Cell lines
The K562 (obtained from the German Resource Center for
Biological Material [DSMZ], DSMZ no. ACC 10), Meg-01
(obtained from the American Type Culture Collection [ATCC],
no. CRL-2021) and HL60 cell lines (kindly provided by Prof. Shay
Izraeli, Sheba Medical Center, Israel) were cultured in RPMI-
1640 medium supplemented with 10% heat-inactivated fetal
bovine serum (FBS), 2 mM glutamine, 1% penicillin and
streptomycin and cultured at 37uC in a humidified incubator
with 5% CO2.
The continuous K562 cell line was originally established from
the pleural effusion of a 53-year-old female with BCR-ABL
positive CML in terminal blast crises. The cell population has been
characterized as highly undifferentiated and of the granulocytic
series.
The Meg-01 cell line was originally derived from bone marrow
cells taken from a patient in megakaryoblastic crisis of BCR-ABL
positive CML.
The HL-60 cell line was originally derived from peripheral
blood leukocytes of a 36-year-old female with acute promyelocytic
leukemia.
Leukocyte isolation
Peripheral blood samples were drawn, with informed consent,
from newly diagnosed CML patients before and on days 5 and 30
of treatment with imatinib at a dose of 100 mg/day on days 1–7,
200 mg/day on days 8–14, 300 mg/day on days 15–21, and
400 mg/day from day 22 and thereafter and from healthy
volunteers. The samples were treated with red-blood-cell lysis
buffer and the remaining leukocytes were used for further
experiments. Only blood samples containing 67–70% granulocytes
(according to routine blood counts) were used. Blood samples,
meeting these criteria, were mixed with erythrocyte lysis buffer
(Qiagen, Germany) and centrifuged at 400 g for 10 min at 4uC.
The leukocyte pellet was washed and centrifuged again. The
remaining leukocytes were snap-frozen and used for further
experiments.
Ethics statement
All healthy volunteers were members of the Experimental
Hematology Lab, Felsenstein Medical Research Center, at the
Rabin Medical Center. Before the experiment, participants were
provided with verbal information outlining the general purpose of
the study and they were informed that they could withdraw at any
time without penalty. They were also verbally informed that the
data obtained from their samples would be confidential and used
only for the purpose of this research. Verbal consent was obtained
for this study because the risks were minimal and all participants
were associates of the Lab, and were therefore familiar with the
basic methods employed in the relevant experiments. The head of
the ethics committee; Institutional Review Board (Helsinki
committee), Rabin Medical Center, Beilinson Hospital, Petah
Tikva, Israel granted us with the following approval in this matter:
"Blood sampling from healthy volunteers who are also research
workers do not require IRB approval in our country. Therefore I
grant you exemption from IRB approval in this matter". Verbal
consent was documented according to IRB ethics committee
procedures. All methods employed in this study were in
accordance with the Declaration of Helsinki.
Studies executed on patient blood samples were performed with
consent. The protocols used were approved by the ethics
committee; Institutional Review Board (Helsinki committee),
Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel.
MiRNA microarray analysis
Microarray analysis was performed on the K562 cell line and on
a pool of leukocytes derived from blood of 3 healthy volunteers.
MiRNAs were extracted from each sample using the miRNeasy
Mini Kit (Qiagen, Germany) according to manufacturer’s
protocol. RNA quantity and quality was assessed using the
Nanodrop and Agilent 2100 bioanalyzer systems, respectively.
Microrna Expression Profile in K562 Cells
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on these assessments. The miRNA microarray experiments were
performed at the Biological Services Unit at the Weizmann
Institute of Science using the Agilent Human miRNA Microarray
Kit version 1.0 (Agilent Technology, USA). For each miRNA,
multiple probes were spotted on the array and the average
intensity of these probes was calculated to represent the expression
value of the miRNA. In addition, multiple spots were included as
negative controls. For each tissue sample, 100ng total RNA was
hybridized with the miRNA array and further processed in
accordance with the manufacturer’s instructions. Two biological
replicates were done for each treatment. The arrays were scanned
using an Agilent Technology G2565BA scanner and the scanned
images were processed using the Feature Extraction software
package version 9.5 (Agilent Technology, USA). Coefficient of
variation (CV) within groups of replicate probes was used as a
quality control measure to reflect the intra-array reproducibility.
Complete raw and normalized microarray data and their MIAME
compliant metadata have been deposited at GEO (www.ncbi.nlm.
nih.gov/geo) under the accession number GSE28825.
Bioinformatics analysis
PartekH genomics suite software. MiRNA microarray
results were analyzed using PartekH Genomics Suite software
V6.5, Copyright 2009 (Partek Inc., St. Louis, MO, USA; www.
partek.com). Data were normalized and summarized with the
robust multi-average method (RMA) [22], using quantile normal-
ization approach [23], followed by Analysis of Variance
(ANOVA). Differentially expressed miRNAs were obtained with
p,0.05 and fold-change cutoff of 4.
MiRNA Target Analysis. Each relevant CML-associated or
treatment-associated miRNA was tested using TargetScan.
TargetScan uses a computational algorithm to predict biological
targets of miRNAs by searching for the presence of conserved
8 mer and 7 mer sites that match the seed region of each miRNA
(http://www.targetscan.org) [24]. All the predicted targets from
this analysis were then used as input for Ingenuity Pathway
Analysis.
Ingenuity Pathway Analysis. Ingenuity Pathway Analysis
(IPA) identifies lists of genes that satisfy particular biological
criteria. IPA scores these genes against pathways in the Ingenuity
Knowledge Base which houses a large database of biological and
chemical relationships extracted from scientific literature. IPA
integrates data from a variety of experimental platforms making it
possible to identify signaling and metabolic pathways, molecular
networks, and biological/disease processes that are most
significantly perturbed in our dataset of interest. For each
analysis, IPA ranks each function or pathway using the right-
tailed Fisher Exact Test, which measures the likelihood that the
lists of genes are associated with a certain pathway/function (www.
ingenuity.com).
KEGG Pathway Database. The predicted targets from our
analysis were also used as input for the KEGG pathway database
[25]. KEGG is used as a reference knowledge base for biological
interpretation of large-scale datasets generated by high-throughput
experimental technologies. KEGG is a collection of manually
drawn pathway maps representing our knowledge on the
molecular interaction and reaction networks for metabolism,
genetic information processing, environmental information
processing, cellular processes and human diseases. . KEGG uses
in-house software called KegSketch (http://www.genome.jp/
kegg/pathway.html).
Utilizing both IPA and KEGG technologies provides clues for
the function of our miRNA of interest.
Venn diagrams. Venn diagrams were used to show all
hypothetically possible logical relations between the top scoring
pathways identified by Partek Genomics Suite software V6.5,
Copyright 2009.
MiRNA-specific real time PCR (miR–qRT-PCR)
MiRNA real-time RT-PCR was performed using the TaqManH
Small RNA primer and probe sets (Applied Biosystems, USA).
RNA was isolated from all cell lines and from leukocytes purified
from blood of CML patients and of healthy volunteers. RNA was
reverse-transcribed with miRNA specific stem-looped RT primers
(Applied Biosystems, USA) and incubated for 30 min at 16uC,
30 min at 42uC and 5 min at 85uC. Real-time PCR was
performed in duplicates using the following conditions: 95uC for
10 min, followed by 40 cycles of 95uC for 15 s, and 60uC for
1 min. Each value of miRNA expression is represented relative to
the expression of U6-snRNA, which was used as an internal
control. The fold change was calculated using 2
2DDCt method.
Real-time PCR
RNA was isolated using RNeasy Plus Mini Kit (Qaigen,
Germany) and reverse transcribed using the high capacity cDNA
RT kit (Ambion, USA). Real-time PCR was then performed using
the SDS 7000 machine (Applied Biosystems, USA) in a 20 ml
reaction containing 10 ng RNA, 10 ml TaqMan master mix
(Ambion, USA), 1 ml of target gene or GUSB RNA control
primers and a FAM dye-labeled TaqMan probe (Ambion, USA).
Amplification conditions were: 50uC for 2 min, followed by 95uC
for 10 min, then 40 cycles of 95uC for 15 sec and 60uC for 1 min.
The DDCt method was used to calculate relative expression levels.
Statistics
Experiments were done in triplicates. Differences were statisti-
cally evaluated by Student’s t-test. Unless otherwise stated, p#0.05
was considered to be statistically significant.
Results
Differentially expressed miRNAs in K562 cells
MiRNA expression has been shown to dramatically change in
CLL, ALL, lymphoma and in other hematological malignancies
[14,15,16]. With the objective of deciphering a potential miRNA
expression signature associated with CML, we analyzed the
miRNAs expression profile of the CML cell line, K562 in
reference to a pool of 3 healthy blood samples using a miRNA-
based microarray chip assay. Of the 470 mature human miRNAs
analyzed, 142 miRNAs showed reasonable expression levels in
these cells (see Materials and Methods). We used unsupervised
hierarchical clustering to differentiate the CML cell line from the
normal tissues (Figure 1). It was encouraging to notice that the
healthy blood tissues were clustered separately from the K562 cell
line indicating a distinct miRNA expression pattern between these
groups. Of the 142 miRNAs remaining in the final analyses; 75
were found to be downregulated in K562 cells as compared to
healthy blood samples (Table 1), whereas only 35 were
upregulated (Table 2), both with a p-value#0.009. These data
are consistent with previous reports stating that overall downreg-
ulation of miRNA expression is characteristic of many cancers, as
compared to their normal tissue counterparts [13,14].
In order to validate the microarray data and to ensure that the
variations observed were biological and not technical we carried
out Taqman miR–qRT-PCR analyses of several miRNAs with
altered expression between the K562 cell sample and the normal
pooled blood sample. We chose a subset of miRNAs for validation;
Microrna Expression Profile in K562 Cells
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potential regulators of cancer/growth pathways in the cell. Each
miRNA was quantified in the sample and its expression level was
normalized to that of the U6-snRNA, which was used as reference.
The miRNA expression patterns from the K562 cells and from the
normal pooled blood sample were consistent between the
microarray and Taqman measurements. Overall, with the aid of
miRNA-based microarray, miR–qRT-PCR and preliminary
bioinformatics analysis, we identified 8 miRNAs with statistically
significant differential expression between K562 cells and healthy
controls: 7 of them were downregulated in K562 cells (miR-31,
miR-34a, miR-143, miR-145, miR-155, miR-196b and miR-564)
and one was upregulated (miR-128) in K562 cells (Figure 2).
To further test whether these miRNAs could be implicated
specifically in the pathogenesis of CML, we analyzed the
expression of the deregulated miRNAs in an additional CML cell
line; Meg-01 and in a different hematological, non-CML cell line;
HL60. Of the 7 miRNAs found to be downregulated in K562, 6
(miR-31, miR-34a, miR-143, miR-145, miR-155, and miR-564)
showed a low expression pattern in Meg-01 cells (Figure 3). The
expression of 2 of these 6 miRNAs, miR-143 and miR-145, was
low in HL60 cells as well indicating that these miRNA are
probably not associated exclusively with CML (data not shown).
The expression of the remaining 4 miRNAs (miR-31, miR-
34a, miR-155, and miR-564) was high in healthy blood and in
HL60 and low in K562 and in Meg-01, indicating a higher
likelihood of these miRNAs to be involved in CML pathogenesis.
BCR-ABL kinase activity induces downregulation of miR-
31, miR-155, and miR-564 in CML
To support the notion that the above mentioned miRNAs are
implicated in CML, we tested the expression of these miRNAs in a
CML patient. The analysis confirmed the statistically significant
difference in the expression of 3 of the 4 miRNAs (miR-31, miR-
155, and miR-564) between leukocytes from a CML patient and
those from healthy donors (Figure 4). As CML is characterized by
Figure 1. Unsupervised clustering analysis of miRNA expression in K562 cells as compared to a pooled sample of healthy blood.
Heat maps illustrating unsupervised clustering of miRNAs that were differentially expressed between blood and K562 samples. The red and blue
colors indicate relatively high and low fold-change of expression, respectively. Missing values are indicated in gray. The 8 miRNAs we focused on are
indicated with arrows at the bottom of the cluster. Blue arrows represent miRNAs whose expression was downregulated in K562 vs blood, the black
arrow represent miRNA whose expression was upregulated in K562 vs blood. Two main miRNAs clusters are shown on top (cluster 1; purple and
cluster 2, orange), correlated with the expression patterns described above.
doi:10.1371/journal.pone.0035501.g001
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abnormal expression of these 3 miRNAs observed in the CML
patient could be dependent on the kinase activity of BCR-ABL.
To test this hypothesis, the expression of these miRNAs was
analyzed in leukocytes of a CML patient before and during
treatment with imatinib. Whereas these miRNAs showed virtually
no change in their expression level on day 5 of imatinib treatment
at a dose of 100 mg/day (for the first week of treatment), 30 days
of treatment with imatinib at a dose of 400 mg/day (from the
fourth week of treatment and thereafter) induced an upregulation
of all 3 miRNAs (Figure 4).
Target and pathway analysis of the identified miRNAs
MiRNAs can regulate numerous target genes and therefore
have the potential to modulate multiple pathways. Several
databases based on various algorithms are available for predicting
Table 1. Summary of miRNAs downregulated in K562 cells as compared to healthy blood samples.
miRNA ID Fold change p-value
Raw log2 values (mean
K562 vs blood) miRNA ID Fold change p-value
Raw log2 values
(mean K562 vs
blood)
hsa-miR-584 4E+07 9E211 0.1 vs 25.16 hsa-miR-513c 53223 0.0006 9.21 vs 24.92
hsa-miR-1299 335610 3E209 0.1 vs 18.45 hsa-miR-148b 2E+09 0.0002 36.62 vs 67.54
hsa-miR-1471 8E+09 7E209 0.1 vs 32.92 hsa-miR-491-3p 4 0.0003 0.1 vs 2.24
hcmv-miR-US4 4E+09 8E209 0.1 vs 32.02 hsa-miR-424 1E+18 0.0008 67.89 vs 129.69
hsa-miR-200c 28 10E209 0.1 vs 4.89 hsa-miR-371-5p 6E+11 0.0002 0.1 vs 39.19
hsa-miR-520f 23894 1E208 0.1 vs 14.64 hsa-miR-193b* 285 0.0004 0.1 vs 8.25
hsa-miR-34a 21899 2E207 0.1 vs 14.51 hsa-miR-150* 2E+16 0.0004 1.38 vs 55.42
hsa-miR-1180 2E+06 2E207 0.1 vs 20.61 hsa-miR-221* 10 0.0005 0.1 vs 3.39
hsa-miR-623 3E+11 8E207 0.1 vs 38.30 hsa-miR-671-5p 2E+28 0.0004 1.93 vs 95.69
hsa-miR-1469 24 1E206 0.1 vs 4.70 hsa-miR-188-5p 3E+22 0.0003 24.39 vs 99.37
hsa-miR-1182 1E+12 4E206 0.1 vs 40.04 hsa-miR-202 8E+11 0.0010 6.17 vs 45.73
hsa-miR-28-5p 6E+22 8E206 0.1 vs 75.63 hsa-miR-1323 1966 0.0009 0.1 vs 11.04
hsa-miR-342-5p 1E+20 8E206 0.1 vs 66.89 hsa-miR-605 41 0.0009 0.1 vs 5.45
hsa-miR-652 9E+25 8E206 37.45 vs 123.67 hsa-miR-765 8E+37 0.0009 0.1 vs 126.0
hsa-miR-665 417 1E205 0.1 vs 8.80 hsa-miR-542-5p 42612 0.002 1.98 vs 17.36
hsa-miR-363 1E+21 1E205 0.1 vs 70.04 hsa-miR-142-5p 5E+35 0.003 65.06 vs 183.66
hsa-miR-564 3E+12 1E205 1.7 vs 42.93 hsa-miR-193a-5p 534 0.002 0.1 vs 9.16
hsa-miR-622 6E+08 2E205 1.6 vs 30.84 hsa-miR-198 293 0.002 0.1 vs 8.30
hsa-miR-1224-5p 4E+26 2E205 0.1 vs 88.40 hsa-miR-22 3E+37 0.007 323.77 vs 448.43
hsa-miR-223* 3E+15 4E205 12.66 vs 96.29 hsa-miR-663 6E+15 0.002 0.1 vs 52.43
hsa-miR-199b-5p 10E+16 3E205 2.7 vs 59.19 hsa-miR-30e* 4E+09 0.004 44.23 vs 76.03
hsa-miR-222 2E+15 3E205 0.1 vs 50.99 hsa-miR-191 10 0.002 0.1 vs 3.37
hsa-miR-582-5p 2E+24 3E205 0.1 vs 80.94 hsa-miR-588 68 0.002 0.1 vs 6.18
hsa-miR-145 7E+20 4E205 26.26 vs 95.56 hsa-miR-134 8E+33 0.002 19.53 vs 132.10
hsa-miR-143 2584 4E205 0.1 vs 11.43 hsa-miR-186 5E+10 0.002 26.64 vs 62.05
hsa-miR-557 1E+08 4E205 0.1 vs 26.68 hsa-miR-760 4E+09 0.003 3.21 vs 35.11
hsa-miR-664* 10E+26 4E205 0.1 vs 89.72 hsa-miR-135a* 106 0.003 0.1 vs 6.82
hsa-miR-31 18 5E205 0.1 vs 4.26 hsa-miR-659 192232 0.003 0.1 vs 17.65
hsa-miR-98 5E+17 6E205 0.1 vs 58.88 hsa-miR-361-3p 9E+09 0.004 11.98 vs 44.97
hsa-miR-199a-5p 3E+22 7E205 0.1 vs 74.59 hsa-miR-518a-5p 19 0.005 0.1 vs 4.34
hsa-miR-1183 4E+21 9E205 0.1 vs 71.99 hsa-miR-650 16 0.005 0.1 vs 4.11
hsa-miR-1300 10E+10 9E205 0.1 vs 36.60 hsa-miR-197 5E+22 0.006 33.08 vs 108.50
hsa-miR-1225-3p 8565 0.0002 0.1 vs 13.16 hsa-miR-196b 16 0.007 0.1 vs 4.13
hsa-miR-149* 13087 0.0001 0.1 vs 13.77 hsa-miR-664 8E+06 0.007 2.61 vs 25.61
hsa-miR-155 2E+27 0.0001 0.1 vs 90.52 hsa-miR-595 4602 0.009 0.1 vs 12.26
hsa-miR-513a-5p 5E+37 0.0002 42.98 vs 168.19 hsa-miR-320c 1E+15 0.009 162.57 vs 212.83
hsa-miR-601 8E+09 0.0001 0.1 vs 32.98 hsa-miR-874 2E+07 0.009 0.1 vs 24.51
hsa-miR-181c 515352 0.0002 0.1 vs 19.07
Shown is the fold change difference expression of K562 cells compared to healthy blood samples (second column from left), and p-value (third column from left), for
each presented miRNA (first column from left). The last column displays raw experimental expression data presented as log2 values (0.1 is background level).
doi:10.1371/journal.pone.0035501.t001
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target genes and signaling pathways implicated in CML, we
analyzed predicted targets of the 3 miRNAs differentially
expressed in this study using the TargetScan Human 5.1 database
(Table 3).
At this point, we sought to correlate the expression of some of
the significantly deregulated miRNAs in K562 with some of their
putative targets as predicted by our bioinformatics analysis. For
this purpose, we performed real-time PCR analysis on CBL, E2F3,
cyclin D1, K-ras and Akt2; five of the most promising target
proteins to be involved in CML.
CBL which is involved in cancer initiation and progression and
is believed to form a multi-protein complex with BCR-ABL
[26,27] is a putative targets of miRs-31 and miR-155. Cyclin D1
and K-ras which have been shown to cooperate with ABL
oncogenes to induce full in-vitro and in-vivo transformation
[28,29] are putative targets of miR-155. E2F3 and Akt2 expression
is important for BCR-ABL clonogenic activity and are putative
targets of miR-564 [30,31]. Given the downregulated expression
of these miRNAs in K562 cells, we hypothesized that the levels of
the above mentioned targets would be elevated in this cell line.
Indeed, we found that the expression level of CBL, E2F3, cyclin
Dl, K-ras and Akt2 to be significantly higher in K562 cells
compared to normal blood samples (Figure 5).
Based on these results, we explored biological significance,
molecular functions and possible diseases affected by the predicted
Table 2. Summary of miRNAs upregulated in K562 cells as compared to healthy blood samples.
miRNA ID Fold change p-value Raw log2 values (mean K562 vs blood)
hsa-miR-495 1E+24 9E205 85.83 vs 5.64
hsa-miR-493* 1E+31 4E205 104.17 vs 1.00
hsa-miR-365 6E+12 0.0001 92.17 vs 49.86
hsa-miR-128 4E+15 0.0003 99.18 vs 47.43
hsa-miR-543 1E+08 0.0004 27.14 vs 0.1
hsa-miR-382 4E+09 0.0032 39.34 vs 7.29
hsa-miR-409-3p 2E+34 0.0004 130.16 vs 16.14
hsa-miR-154 2E+09 0.0007 30.63 vs 0.1
hsa-miR-654-3p 1E+34 0.0001 120.35 vs 7.06
hsa-miR-193b 6E+22 0.0003 75.81 vs 0.1
hsa-miR-409-5p 5E+08 4E205 28.83 vs 0.1
hsa-miR-379 7E+25 0.002 85.99 vs 0.1
hsa-miR-432 2E+11 0.003 49.95 vs 12.23
hsa-miR-21* 1E+06 0.0007 43.76 vs 23.43
hsa-miR-18a* 791 0.0007 9.73 vs 0.1
hsa-miR-181b 1E+14 0.005 97.43 vs 50.69
hsa-miR-329 4E+10 0.003 53.21 vs 0.1
hsa-miR-105 6864 0.003 12.85 vs 0.1
hsa-miR-410 4E+20 0.003 76.29 vs 7.78
hsa-miR-96 9E+16 0.004 56.35 vs 0.1
hsa-miR-758 1E+16 0.003 53.49 vs 0.1
hsa-miR-411 5E+08 0.007 28.85 vs 0.1
hsa-miR-431 1E+18 0.004 66.07 vs 5.99
hsa-miR-299-3p 5E+14 0.003 48.98 vs 0.1
hsa-miR-337-5p 5E+13 0.004 45.45 vs 0.1
hsa-miR-92a-1* 7E+18 0.001 62.59 vs 0.1
hsa-miR-151-3p 8E+15 0.002 95.62 vs 42.78
hsa-miR-431* 1E+16 0.001 53.52 vs 0.1
hsa-miR-323-3p 8E+11 0.008 39.69 vs 0.1
hsa-miR-154* 3E+34 0.002 114.72 vs 0.1
hsa-miR-320a 7E+28 0.006 192.48 vs 96.57
hsa-miR-9 1E+15 0.007 50.01 vs 0.1
hsa-miR-338-5p 7132 0.009 18.90 vs 6.1
hsa-miR-335* 12549 0.009 13.71 vs 0.1
hsa-miR-486-3p 6E+06 0.002 22.58 vs 0.1
Shown is the fold change difference expression of K562 cells compared to healthy blood samples (second column from left), and p-value (third column from left), for
each presented miRNA (first column from left). The last column displays raw experimental expression data presented as log 2 values (0.1 is background level).
doi:10.1371/journal.pone.0035501.t002
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PLoS ONE | www.plosone.org 6 April 2012 | Volume 7 | Issue 4 | e35501Figure 2. Real-time RT-PCR validation of microarray results, presenting changes in miRNA expression in K562 cells as compared to
a pooled sample of healthy blood. The expression of A. miR-31, B. miR-34a, D. miR-143, E. miR-145, F. miR-155, G. miR-196b and H. miR-564 was
downregulated whereas the expression of C. miR-128 was upregulated in K562 cells compared to healthy blood. The histograms show percentage of
miRNA expression normalized to U6-snRNA6SEM from at least 3 experiments. Insets show microarray expression results for the specified miRNAs
(Blood: red circles; K562: blue circles).
doi:10.1371/journal.pone.0035501.g002
Figure 3. Expression analysis of miRNAs in CML-derived cell
lines as compared to a pooled sample of healthy blood.
Expression analysis of miR-31, miR-34a, miR-143, miR-145, miR-155 and
miR-564 in Meg-01 and K562 cell lines and in healthy blood samples
was analyzed by miR–qRT-PCR. Shown is the percentage of miRNA
expression normalized to U6-snRNA6SEM from at least 3 experiments.
doi:10.1371/journal.pone.0035501.g003
Figure 4. Expression analysis of miRNAs in a CML patient
before and during treatment with imatinib. Expression analysis of
miR-31, miR-155 and miR-564 in a CML patient at diagnosis an on day 5
of imatinib treatment at a dose of 100 mg/day (for the first week of
treatment) and on day 30 of imatinib treatment at a dose of 400 mg/
day (from the fourth week of treatment and thereafter). Expression was
analyzed by miR–qRT-PCR. Shown is the percentage of miRNA
expression normalized to U6-snRNA6SEM from at least 3 experiments.
doi:10.1371/journal.pone.0035501.g004
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pathway analysis software (Table 4). Reassuringly, the analysis
identified cancer as the main disease associated with expression of
these 3 deregulated miRNAs, and specifically CML as one of the
major neoplasms linked to these miRNAs. Colorectal cancer was
an additional prominent disease found to be related to these
deregulated miRNAs. The MAPK, ErbB, mTOR and VEGF
signaling pathways were the main molecular pathways related with
these expression patterns. In addition to Ingenuity Systems
pathway analysis, KEGG pathway analysis also demonstrated
CML as one of the main diseases associated with these miRNAs.
Figure 6 shows the molecular pathways, as analyzed by the KEGG
pathway database, which may be deregulated in CML due to
improper expression of the target genes summarized in Table 3, as
a result of the deregulated miRNAs. These pathways correlate
with cell survival and uncontrolled cell proliferation. Next, we
wanted to hypothetically establish possible logical relations
between the top scoring pathways identified by our analyses.
Interestingly, according to Venn diagram analysis, there is an
overlap between the CML-related miRNAs and the MAPK, ErbB,
mTOR and VEGF signaling pathways-related miRNAs (Figure 7).
Overall, the data derived from our miRNA profiling and
bioinformatics analysis support the notion that the miRNAs
identified in this study may have a pivotal role in CML.
Nevertheless, while these data point to a central disease, the
precise molecular pathways targeted by these miRNAs are
variable implying a high level of complexity of miRNA target
selection and regulation.
Discussion
Distinct miRNA expression signatures are known to participate
in regulatory pathways involved in the development and
progression of many types of tumors. Accordingly, to date, all
tumors tested have shown significantly different miRNA profiles
compared with normal cells from the same tissue. These miRNA
expression signatures have been reported to be associated with
diagnosis, prognosis and response to treatment [32]. Since
miRNAs affect a wide range of molecular pathways, studying
miRNA expression in human cancer may provide a better
understanding of the molecular pathways contributing to cancer
pathogenesis and progression.
We utilized miRNA microarray analysis and miRNA real-time
PCR to detect miRNAs whose expression is deregulated in CML.
To demonstrate whether different sets of miRNAs may properly
classify our groups of interest, we performed unsupervised cluster
analysis using Partek Genomics Suite software. The unsupervised
cluster analysis generated a tree that clearly separated healthy
blood samples from K562 cells suggesting that this miRNA profile
may serve as a marker differentiating CML patients from healthy
individuals. In general, a higher percentage of miRNAs were
downregulated rather than upregulated in K562 cells as compared
to normal blood samples. This is in agreement with the
acknowledged concept that overall downregulation of miRNA
expression is characteristic of many cancers, as compared to their
normal tissue counterparts [13,14].
In this study we identified 3 miRNAs (miR-31, miR-155,
and miR-564) to be abnormally downregulated in CML cell lines
and in patients with CML as compared to non-CML cell lines and
to healthy blood samples thus providing support to our hypothesis
that miRNAs could be implicated in CML. Moreover, our data
suggest that the low expression of these miRNAs is dependent on
BCR-ABL tyrosine kinase activity as demonstrated by their
increased expression in leukocytes of an imatinib treated patient.
Further studies are required to address the molecular mechanism
by which BCR-ABL is responsible for the downregulated
expression of these miRNAs and whether this downregulation is
Table 3. Putative target genes of the deregulated miRNAs as
predicted by Target Scan analysis.
miR-31 Q miR-155 Q miR-564 Q
CBL CBL CBL
E2F2 E2F2 E2F2
E2F3 E2F3
Cyclin D1 Cyclin D1
TGFbR2 TGFbR2
K-ras K-ras
PIK3R1 PIK3R1
SOS1 SOS1
Akt2 Akt2
p-value 0.58 9.1E207 3.04E205
Arrows indicate the expression of the miRNA in CML cell lines and patients in
reference to its expression in non-CML cell lines and healthy blood.
Abbreviations are as follows: CBL, Casitas B-lineage lymphoma; TGFbR,
transforming growth factor-beta receptor; K-ras, Kirsten rat sarcoma; PIK3R1,
phosphatidylinositol 3-kinase regulatory subunit alpha; SOS1, son of sevenless
homolog 1.
doi:10.1371/journal.pone.0035501.t003
Figure 5. Expression of putative targets of the derugulated
miRNAs. Expression of CBL, E2F3, cyclin D1, K-ras and Akt2 was
analyzed by real-time PCR in K562 cells and in healthy blood samples.
Shown is the percentage of miRNA expression normalized to GUSB
RNA6SEM from at least 3 experiments.
doi:10.1371/journal.pone.0035501.g005
Table 4. Ingenuity analysis of miRNA predictive pathways.
miR-31/miR-155/miR-564
Disease Colorectal cancer
CML
Molecular pathway T/B cell receptor signaling pathway
MAPK signaling pathway
ErbB signaling pathway
mTOR signaling pathway
VEGF signaling pathway
doi:10.1371/journal.pone.0035501.t004
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One miRNA that we found to be downregulated in CML is
miR-155. Several lines of evidence suggest that this miRNA may
have an important role in normal hematopoiesis [33]. Similar to
our quest for defining a signature expression pattern associated
with CML, Calin et al. defined a unique miRNA signature linked
with prognostic factors and disease progression in CLL. This
unique signature was composed of 13 miRNA, among them was
miR-155 [34]. However, in contrast to our findings, this miRNA
has been reported to accumulate in several lymphoma subtypes,
especially in diffuse large B cell lymphoma [35], Hodgkin
lymphoma [36] Burkitt lymphoma [37] and in CLL [38]. These
discrepancies may be due to differences in the malignancy
investigated. They could also be derived from technical differences
influenced by the type of technique used for the identification of
the relevant miRNA. Also, differences in the normal control used
could also have influenced the outcome of the miRNA profiling
analysis.
MiR-31, which was also shown to be downregulated in our cell
model, is one miRNA out of a cluster of miRNAs that have been
assigned to 9 p (miRBase, http://microrna.sanger.ac.uk/) and
documented as recurrently deleted when 9 p instability is present,
such as witnessed in many CML cases [39]. MiR-31 has recently
been shown to concurrently repress the expression of multiple
prometastatic target genes thereby inhibiting several distinct
aspects of the invasion-metastasis cascade including motility,
invasion and resistance to anoikis. As evidence, overexpression
of miR-31 in otherwise-aggressive breast tumor cells suppresses
metastasis. Whereas inhibiting miR-31 in-vivo allows otherwise-
nonaggressive breast cancer cells to metastasize [40]. In contrast to
these and to our results, miR-31 was shown to be upregulated in
colorectal tumor cells in comparison to non-tumor adjacent
mucosa and in plasma of oral squamous cell carcinoma [41,42]
Expression of miR-564, which we found to be downregulated in
our setting, has not been evaluated previously in CML, and the
published data regarding this miRNA seems to be inconsistent. It
was shown to be downregulated in multiple myeloma, upregulated
in CLL and baring no significant change in expression level in
hairy cell leukemia compared with normal levels [43].
Ingenuity Systems pathway analysis and KEGG pathway
analysis identified CML as one of the major neoplasms linked to
these deregulated miRNAs. This analysis also recognized the
MAPK, ErbB, mTOR and VEGF signaling pathways as the main
molecular pathways related with these expression patterns. These
signaling pathways usually participate in a wide range of cellular
processes such as growth, proliferation, differentiation and
apoptosis. These pathways have continuously been reported to
play an important role in hematological malignancies in general
Figure 6. KEGG pathways of deregulated miRNAs predicted targets in CML. This figure presents cell survival and growth signaling
pathways within a CML cell. Red squares represent proteins encoded by genes targeted by the deregulated miRNAs. We have shown that the miRNAs
regulating these target genes are downregulated in CML. As a result, these target genes are probably upregulated leading to increased cell survival
and induced of uncontrolled cell proliferation.
doi:10.1371/journal.pone.0035501.g006
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shown to activate mTOR and MAPK signaling cascades. These
pathways are important components of the aberrant signaling
induced by BCR-ABL and contribute to BCR-ABL leukemogen-
esis. (reviewed in [44,45,46,47]).
In order to determine potential genes implicated in CML, we
analyzed predicted targets of the 3 miRNAs differentially
expressed using several different algorithms. Nine predicted targets
of the 3 deregulated miRNAs have a p-value#0.005. Most of these
targets have been published as related to CML [30,48,49,50,51].
We observed a downregulation in the expression of the miRNAs
targeting Akt2, CBL, E2F2, E2F3, Cyclin Dl, K-ras, PIK3R1,
SOS1 and TGFbR2 in CML cell lines and patients as compared
to healthy blood. We can therefore hypothesize that the levels of
these targets would be elevated in CML cell lines and patients. To
begin to confirm the biological effects of these deregulated
miRNAs, the expression of CBL, E2F3, cyclin Dl, K-ras and
Akt2 was studied. Interestingly, the expression of these proteins
was indeed found to be upregulated in K562 cells compared to
healthy cells.
Among the possible targets for these miRNAs we found several
to mediate transformation of primary human hematopoietic cells.
We found that miRs-31 and -155, which were downregulated in
our setting, potentially target CBL, which is involved in cancer
initiation and progression and was originally discovered as an
oncogene which induces B-cell and myeloid leukemias in mice
[52]. The expression of this target protein was found to be elevated
in K562 cells as compared to control cells. The emerging view is
that BCR-ABL assembles a multi-protein complex whose signaling
output leads to cellular transformation. Among other proteins,
CBL has been identified as participating in this multi-protein
complex and as being phosphorylated by BCR-ABL. As a result of
these interactions many intracellular signaling pathways, partici-
pating in cellular proliferation and survival, are activated,
including the K-ras, Akt2 and STAT pathways [26,27].
E2F3 is an addition protein known to be important for BCR-
ABL leukemogenic potential [30]. E2F3 mRNA level has been
reported to be higher in BCR-ABL-expressing cell lines compared
with non BCR-ABL-expressing cells, and decreases upon inhibi-
tion of BCR-ABL kinase activity. Eiring et al have suggested that
E2F3 plays a major role in controlling BCR-ABL oncogenic
activity and that its expression is required for in-vivo BCR-ABL
leukemogenesis. In addition, they show enhanced proliferation to
be a characteristic of CML-blast crisis cells, where E2F3 mRNA
levels are high but not of CML-chronic phase cells, where E2F3
mRNA levels are low [30]. Our data reveal that miR-564, a
putative regulator of E2F3, is downregulated in CML. It is possible
that the reduced expression of miR-564 leads to an enhanced
Figure 7. Overlap of predicted target genes. A Venn diagram showing the overlap between predicted targets of CML-related miRNAs and
miRNAs related to the different pathways that are predicted to be deregulated in our study.
doi:10.1371/journal.pone.0035501.g007
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ABL and the growth advantage seen in CML-blast crisis cells.
An additional protein shown to cooperate with BCR-ABL to
induce full cellular transformation is cyclin D1. Afar et al have
shown that cells overexpressing cyclin Dl (and not cyclin E) and
BCR-ABL formed more numerous and larger colonies in soft agar
than cells expressing ABL alone [28]. The upregulated expression
of cyclin D1 witnessed in K562 cells has been proposed to be
achieved through its highly active promoter in these cells [53].
Alternatively, the enhanced expression of cyclin D1 in these cells
could be attributed to the reduced expression of miR-155
putatively regulating it.
Ras signaling pathways are activated by a spectrum of
hematopoietic cytokine receptors and therefore play important
roles in the proliferation and enhanced survival of hematopoietic
progenitors. For instance, genetic and biochemical data argue that
Ras activation plays a central role in leukemogenic transformation
by BCR-ABL [29]. Nevertheless, activating K-ras mutations are
detected more often in solid tumors and are a rare event in
hematological malignancies in general and in CML in particular
[54,55]. In the absence of oncogenic Ras mutations, alternative
mechanisms activating Ras, such as oncogenic activation of
upstream tyrosine kinases as seen in AML cells [56,57,58,59]
and loss-of-function mutations in the Ras-GAP protein; neurofi-
bromatosis 1 as seen in juvenile myelomonocytic leukemia
(JMML) [60], have been suggested. We found the expression of
miR-155, a putative negative regulator of K-ras, to be impressively
downregulated in CML cell lines and patients. A decrease in miR-
155 may serve as an additional mechanism leading to deregulated
expression of oncogenic Ras.
Akt2 and Akt3, are genomically amplified in several ovarian,
pancreatic and breast cancers [61,62]. In addition, in a study
performed to elucidate the molecular mechanisms underlying
CML disease progression, whole-genome profiling was performed
to identify recurrent submicroscopic gains and losses of genetic
material. In this study, gains for Akt2 were observed [31]. These
data propose that overexpression of Akt2 may contribute to the
CML malignant phenotype or to malignant disease progression.
We also detected a high expression level of Akt2 in K562 cells. We
however suggest that this upregulated expression might be due to
decreased expression of miR-564, putatively regulating Akt2, in
K562 cells.
In this study we identified 3 miRNAs deregulated in CML cell
lines and patients versus non-CML cell lines and healthy cells. The
presented data suggest that numerous miRNA genes are
implicated in the regulation of multiple pathways in hematopoiesis
and when aberrantly expressed may promote CML predisposition,
initiation and progression. Our identification of CML-related
miRNAs and their putative targets can be used as a basis to
explore the functions of these miRNAs. Nevertheless, further large
scale studies and comprehensive analyses are imperative to
validate the role of these miRNAs in CML and to determine
whether selective miRNA targeting might modify disease pheno-
type and outcome. In addition, studies including introduction of
exogenous miRNAs or antisense to miRNAs are needed to
confirm the direct relationship between each miRNA and its
putative target. Ultimately, such studies will have a guiding
significance in research and clinical applications and will hopefully
aid in the development of novel therapeutic strategies and in
determining if these deregulated miRNAs and their targets could
be used as diagnostic or prognostic indicators.
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